Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com Is Abbott's January Pullback a Good Time to Buy? Author: Thomas Hughes. Article Posted: 1/24/2026. 
Key Takeaways - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making the stock look attractively valued. The move, driven more by market angst than by any clear fundamental weakness, appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
A major force in the crypto world is quietly becoming one of gold's most aggressive buyers — and most investors have no idea it's happening.
A longtime gold analyst says profits from a leading stablecoin operation are being funneled into physical gold at a scale that could materially impact supply and demand. After a recent meeting with insiders, he began outlining what this trend could mean for gold prices and a small group of companies positioned to benefit. Read the full gold briefing here The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction — a period during which institutions actively accumulated the stock. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that a few metrics missed the street's expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Top-line growth lagged by several hundred basis points, but margin expansion helped offset the shortfall: adjusted earnings per share (EPS) rose about 12%, coming in slightly above consensus. By segment, the results highlighted the strength of Abbott’s diversified healthcare portfolio. The Nutrition and Diagnostic segments contracted — Nutrition fell nearly 9% — but solid gains in Established Pharmaceuticals and Med Tech more than offset those declines. Established Pharmaceuticals grew roughly 9%, driven by generics and emerging markets, while Med Tech increased about 12.3%, with broad strength across its sub-segments. Margins improved, although not quite to the level some analysts had expected. A favorable product mix, strength in Med Tech, lower COVID-19-related sales and operational improvements all contributed to the margin gains. Management expects that trend to continue, forecasting roughly 10% earnings growth in 2026, outpacing revenue growth and supporting the company's capital-return plans. Abbott’s capital returns are a central part of the investment case. The company is a Dividend King, having increased its payout for more than 50 consecutive years, and it appears capable of continuing that streak. After the pullback, the stock yields about 2.5%, and Abbott currently pays out under 50% of earnings, leaving room to fund share buybacks and other uses of cash that can help offset dilution from share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or price-target changes the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while investing in growth. MarketBeat's consensus share-price target implies upside of as much as 30%, which could push the stock to new all-time highs, while even the low-end targets suggest modest upside from current levels. Key catalysts include an expanding Med Tech portfolio, greater AI integration across operations and products, margin improvement, and strategic acquisitions. The purchase of Exact Sciences is one recent example that broadens Abbott's revenue and profit streams and enhances its product pipeline. The recent sell-off has been severe and could deepen. However, institutions that accumulated shares throughout 2025 are likely to add at discounted prices. Early technical indications show support in the $105 to $110 range, though that level is not yet confirmed. There is a risk that ABT could slide to the low end of the buy zone — potentially near $95 or below — before staging a rebound.
| 
